Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI breathes easy after Spiriva trumps LABAs in old school German HTA

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim's top selling drug, Spiriva (tiotropium) offers additional benefit compared to placebo and long-acting beta-2 agonists (LABAs), says a report from IQWiG, Germany's Institute of Quality and Efficiency in Healthcare. The findings mark a more positive endorsement of the drug than the institute's previous report published in November, which concluded that Spiriva offered additional benefit in comparison only to one LABA, salmeterol.

You may also be interested in...



USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Topics

UsernamePublicRestriction

Register

SC018589

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel